Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2021) 80 P5 | DOI: 10.1530/endoabs.80.P5

UKINETS2021 Poster Presentations Abstracts (12 abstracts)

Real world overall survival in patients with gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in a large United Kingdom (UK) tertiary centre

Dominique Clement 1 , Sarah Brown 1 , Mohammed Halim 1 , Saoirse Dolly 2 , Nabil Kibriya 1 , Mark Howard 1 , Andreas Prachalias 1 , Krishna Menon 1 , Parthi Srinivasan 1 , John Ramage 1 & Raj Srirajaskanthan 1

1King’s College Hospital, London, United Kingdom; 2Guy’s and St. Thomas’ Hospital, London, United Kingdom

Introduction: The incidence and prevalence of GEP-NENs is rising worldwide. NENs represent the group off well differentiated neuroendocrine tumours (NET) and poorly differentiated neuroendocrine carcinoma (NEC). NETs can be divided into grade 1 (G1), grade 2 (G2) and grade 3 (G3) based on histological parameters. There exist several studies regarding survival data but these are mainly based on national databases.

Aim: To describe the real world overall survival of a large UK cohort of patients with GEP-NENs regardless any stage or treatment.

Methods: A retrospective study on all patients recorded in our local database (2000-September 2021) with any type of GEP NEN was performed. Additional data regarding, age, sex, grading and overall survival (OSS) were collected. For OSS the NHS spine was checked on 6 September 2021. Kaplan Meier curves for survival analysis were performed and a log rank test for statistical analysis.

Results: A total of 1158 patients, 589 male (51%) with median age 61 year (IQR 49 – 70 year) could be included. The primary tumour was in the stomach n = 34 (3.4%), duodenum n = 51 (4.4%), pancreas 388 (33.5%), small bowel 362 (33.1%), appendix n = 90 (7.8%), colon n = 23 (2%), rectum n = 55 (4.7%), gallbladder n = 3 (0.3%), oesophagus n = 2 (0.2%), ampulla n = 7 (0.6%), bile duct n = 4 (0.3%) and unknown primary n = 134 (11.6%). The tumours were G1 n = 424 (36.6%), G2 n = 217 (18.7%), G3 n = 50 (4.3%), NECs n = 59 (5.1%). The median OSS for the entire cohort was 102.6 months and for G1-G3 NETs 126 months. The 5-year survival rate is 60%. There is a significant (P = 0.031) difference in OSS for female vs male patients.

Conclusion: This study reports on the median OSS from a real world cohort of patients with GEP-NENs in the UK including also more rare cases such as bile duct, gallbladder and ampulla NENs. Further prospective research is necessary to explore the differences between OSS in this real world cohort and national database based studies.

Article tools

My recent searches

No recent searches.